Lacosamid Hameln (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. By stabilizing these channels, it limits repetitive neuronal firing and diminishes the spread of epileptic activity, thereby contributing to seizure control.

The appropriate dose of Lacosamid Hameln is determined by the prescribing clinician based on the patient’s clinical condition, age, renal and hepatic function, and response to therapy. No standardized dosing regimen is provided here; the prescriber sets the regimen.

Safety data for lacosamide during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Lacosamide differs from many traditional antiepileptics such as carbamazepine or phenytoin by selectively enhancing slow inactivation of sodium channels, which may result in a distinct side‑effect profile and lower risk of certain drug‑induced arrhythmias. It is often chosen when patients require a different mechanism of action or have intolerance to other agents.

Lacosamid Hameln must be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If temperature excursions occur, discard the product according to local regulations.

The product is administered intravenously by slow infusion, typically over 15‑30 minutes, under the supervision of a qualified healthcare professional. The exact infusion rate and duration are determined by the prescribing physician based on the patient’s clinical status.

Serious adverse events include cardiac conduction abnormalities such as PR‑interval prolongation, arrhythmias, suicidal thoughts or behaviors, severe skin reactions like Stevens‑Johnson syndrome, and hypersensitivity reactions that may be life‑threatening. Patients should be monitored for these signs, especially during initiation and dose changes.

Lacosamid Hameln is contraindicated in patients with known hypersensitivity to lacosamide or any component of the formulation. Caution is also advised for individuals with significant cardiac conduction disorders, severe renal or hepatic impairment, and those taking medications that may cause dangerous drug interactions.